Source: Healio News
The FDA approved a combination of carfilzomib, a subcutaneous formulation of daratumumab, and dexamethasone for certain patients with relapsed or refractory multiple myeloma.
The expansion of the carfilzomib (Kyprolis, Amgen) prescribing information to include use with daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech) and dexamethasone applies to adults with multiple myeloma who received up to three previous lines of therapy.
“The addition of subcutaneous daratumumab to Kyprolis plus dexamethasone will offer increased flexibility and convenience for patients with